ArticleScientific reports2025
Controlling intraoperative hyperglycemia in the cardiac surgical patient using the computerized electronic insulin dose calculator.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative hyperglycemia is associated with increased morbidity and mortality. We report the findings of our quality improvement project on the use of an electronic insulin dosing calculator (EIC) to reduce intraoperative hyperglycemia in a cohort of cardiac surgical patients. A pilot and a modified EIC were sequentially implemented in adult patients undergoing cardiopulmonary bypass (CPB) procedures. Outcome measures (average blood glucose (BG) before, during and after CPB), process measures (percent EIC implementation) and balancing measures (incidence of hypoglycemia and average insulin doses utilized) were compared between baseline (no-protocol), pilot and modified EIC periods. 248, 142, and 239 patients were enrolled during the baseline, pilot and modified EIC phases, respectively. The EIC was implemented in 97% (138 out of 142 patients) during the pilot phase and in 86% of patients (206 out of 240 patients) during the modified EIC phase. Average BG levels on CPB were highest at baseline compared with pilot and modified EIC phases (mean, SD, 209 mg/dl,+/-45), vs. 189.8,+/-38 mg/dl vs. 188 mg/dl, +/-40) mg/dl, respectively, p = 0.002). Mean BG values were highest at baseline compared to pilot and modified EIC phases at end of procedure (182.4, +/-49 mg/dl, vs. 122, +/-30 mg/dl, vs.123.3, mg/dl, +/-38.3, vs., respectively, p = < 0.001) and at the ICU (164 ,+/-44.4, mg/dl, vs. 140, +/-37.9 mg/dl, vs. 143.4, +/-36 mg/dl, respectively p = < 0.001). Hypoglycemia was significantly lower during EIC phase compared with baseline (1% vs. 7%, p = 0.008). Less insulin was used during the pilot and modified EIC phases compared to baseline (15.2, +/-10.3, U vs. 15.8, +/-10.2 U, vs. 31.6 +/-20.27 U, respectively, p = 0.006). These preliminary findings suggest EIC effectiveness in reducing intraoperative hyperglycemia in patients undergoing CPB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.